Shopping Cart 0
Cart Subtotal
USD 0

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype-Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype-Pipeline Review, H2 2017' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Overview 6

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Products under Development by Universities/Institutes 16

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Companies Involved in Therapeutics Development 24

Eisai Co Ltd 24

Eli Lilly and Company 25

Kaken Pharmaceutical Co Ltd 25

Ono Pharmaceutical Co Ltd 26

RaQualia Pharma Inc 26

Rottapharm Biotech Srl 27

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Drug Profiles 28

AAT-008-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CR-6086-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

E-7046-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ER-886046-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

grapiprant-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

KAG-308-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ONO-4578-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

P-001-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule to Agonize EP4 Receptor for Osteoporosis-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Dormant Products 41

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Discontinued Products 42

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Product Development Milestones 43

Featured News & Press Releases 43

Jul 25, 2012: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In Japan 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Molecule Types, H2 2017 22

Number of Products by Stage and Molecule Types, H2 2017 22


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 23

Pipeline by Eisai Co Ltd, H2 2017 24

Pipeline by Eli Lilly and Company, H2 2017 25

Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017 25

Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 26

Pipeline by RaQualia Pharma Inc, H2 2017 26

Pipeline by Rottapharm Biotech Srl, H2 2017 27

Dormant Projects, H2 2017 41

Discontinued Products, H2 2017 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutic Products under Development, Key Players in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Overview, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Assessment


Companies

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutic Products under Development, Key Players in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Overview, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Assessment

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype-Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype-Pipeline Review, H2 2017' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Gastrointestinal, Dermatology, Metabolic Disorders, Respiratory and Women's Health which include indications Autoimmune Disorders, Breast Cancer, Allergies, Chronic Pain, Contact Dermatitis, Inflammatory Bowel Disease, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Bladder Cancer, Cervical Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Endometriosis, Epithelial Ovarian Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Inflammatory Pain, Lung Cancer, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Overview 6

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Products under Development by Universities/Institutes 16

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Companies Involved in Therapeutics Development 24

Eisai Co Ltd 24

Eli Lilly and Company 25

Kaken Pharmaceutical Co Ltd 25

Ono Pharmaceutical Co Ltd 26

RaQualia Pharma Inc 26

Rottapharm Biotech Srl 27

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Drug Profiles 28

AAT-008-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CR-6086-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

E-7046-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ER-886046-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

grapiprant-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

KAG-308-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

ONO-4578-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

P-001-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecule to Agonize EP4 Receptor for Osteoporosis-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Dormant Products 41

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Discontinued Products 42

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)-Product Development Milestones 43

Featured News & Press Releases 43

Jul 25, 2012: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In Japan 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Molecule Types, H2 2017 22

Number of Products by Stage and Molecule Types, H2 2017 22


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 23

Pipeline by Eisai Co Ltd, H2 2017 24

Pipeline by Eli Lilly and Company, H2 2017 25

Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017 25

Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 26

Pipeline by RaQualia Pharma Inc, H2 2017 26

Pipeline by Rottapharm Biotech Srl, H2 2017 27

Dormant Projects, H2 2017 41

Discontinued Products, H2 2017 42

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutic Products under Development, Key Players in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Overview, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Assessment


Companies

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutic Products under Development, Key Players in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Therapeutics, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Overview, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline, Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) Pipeline Assessment